Enveric Biosciences (NASDAQ:ENVB) Trading 1.9% Higher – Time to Buy?

Enveric Biosciences, Inc. (NASDAQ:ENVB)’s stock price traded up 1.9% during trading on Monday . The stock traded as high as $1.6299 and last traded at $1.60. Approximately 83,980 shares traded hands during trading, a decline of 25% from the average session volume of 111,233 shares. The stock had previously closed at $1.57.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ENVB. Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Friday, July 17th. Wall Street Zen raised shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Enveric Biosciences presently has an average rating of “Sell”.

Enveric Biosciences Trading Up 1.9%

The firm’s 50 day moving average is $1.54 and its two-hundred day moving average is $2.26. The firm has a market cap of $5.89 million, a P/E ratio of -0.07 and a beta of 1.13.

Enveric Biosciences (NASDAQ:ENVB) last issued its earnings results on Friday, May 15th. The company reported ($1.08) EPS for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.